Classic Familial Adenomatous Polyposis Treatment Market Segmentation:
End user Segment Analysis
In end user segments, the hospital segment is expanding and expected to reach the classic familial adenomatous polyposis treatment market share of 55.4% in 2037. As Hospitals are the main treatment facilities for familial adenomatous polyposis, which treat 90.4% of surgical procedures, such as prophylactic colectomies and restorative proctocolectomies, as per NIH.gov. Academic medical centers are referral sites for complicated cases, with 45.9% of FAP surgical procedures at tertiary care centers in North America and Europe. These centers have specialized units for colorectal cases with multidisciplinary teams working there, and the average cost of treatment ranges from USD 35,050 to USD 75,050 per procedure. Hospital use of robotic-assisted surgery systems has grown 25.6% per year since 2022, cutting down on average length of stay to nearly 5 days.
Distribution Channel Segment Analysis
Under the distribution channel, the hospital pharmacies are leading the classic familial adenomatous polyposis treatment market and are expected to have a market share of 50.3% by 2037. Hospital Pharmacies control FAP treatment distribution and is fueled by centralized buying of high-priced surgical adjuncts such as NSAIDs, immunosuppressants and adherence to FDA-mandated storage procedures for biologics. According to the CMS report, retail pharmacies are poised to maintain a 30.6% share providing post-operative prescription refills, with 15.9% YoY volume growth in sulindac dispensing due to Medicare Part D coverage increase in 2024. Meanwhile, online pharmacies are increasing their sales of genetic testing kits, with USD 50.7 million in yearly sales of at-home APC mutation tests.
Our in-depth analysis of the global classic familial adenomatous polyposis treatment market includes the following segments:
|
Segment |
Subsegment |
|
Treatment Type |
|
|
Distribution Channel |
|
|
End user |
|
